TET1 (Methylcytosine dioxygenase TET1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Hepatocellular carcinoma, Testicular germ cell tumours and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Dioxygenase that plays a key role in active DNA demethylation, by catalysing the sequential oxidation of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). In addition to its role in DNA demethylation, plays a more general role in chromatin regulation by recruiting histone modifying protein complexes to alter histone marks and chromatin accessibility, leading to both activation and repression of gene expression. Plays therefore a role in many biological processes, including stem cell maintenance, T- and B-cell development, inflammation regulation, genomic imprinting, neural activity or DNA repair. Involved in the balance between pluripotency and lineage commitment of cells and plays a role in embryonic stem cells maintenance and inner cell mass cell specification. Together with QSER1, plays an essential role in the protection and maintenance of transcriptional and developmental programs to inhibit the binding of DNMT3A/3B and therefore de novo methylation. May play a role in pancreatic beta-cell specification during development. Location: Nucleus; Chromosome (UniProt). Locus 10q21.3 (HGNC).
- Colorectal cancer: Open Targets association 0.55 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COAD)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Testicular germ cell tumours: IntOGen driver in 1 cohort (MGCT)
- Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC)
- Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)
- Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"TET1" OR ABSTRACT:"TET1" OR TITLE:"tet methylcytosine dioxygenase 1" OR ABSTRACT:"tet methylcytosine dioxygenase 1" OR TITLE:"Methylcytosine dioxygenase TET1" OR ABSTRACT:"Methylcytosine dioxygenase TET1" OR TITLE:"KIAA1676" OR ABSTRACT:"KIAA1676" OR TITLE:"bA119F7.1" OR ABSTRACT:"bA119F7.1" OR TITLE:"CXXC6" OR ABSTRACT:"CXXC6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TET1, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tet1.json. Licence CC BY-NC 4.0.